sabatolimab + azacitidine + venetoclax
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndrome (MDS)
Conditions
Myelodysplastic Syndrome (MDS)
Trial Timeline
May 31, 2021 → May 8, 2023
NCT ID
NCT04812548About sabatolimab + azacitidine + venetoclax
sabatolimab + azacitidine + venetoclax is a phase 2 stage product being developed by Novartis for Myelodysplastic Syndrome (MDS). The current trial status is terminated. This product is registered under clinical trial identifier NCT04812548. Target conditions include Myelodysplastic Syndrome (MDS).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04812548 | Phase 2 | Terminated |
Competing Products
20 competing products in Myelodysplastic Syndrome (MDS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| JSP191 | Jasper Therapeutics | Phase 1 | 25 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 52 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 52 |
| decitabine + decitabine | Eisai | Phase 2 | 52 |
| decitabine + azacitidine | Eisai | Approved | 85 |
| Decitabine | Eisai | Phase 2 | 52 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 33 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 52 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 33 |
| Decitabine | Eisai | Phase 2 | 52 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 41 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 41 |
| Decitabine | Johnson & Johnson | Phase 2 | 52 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 52 |